Literature DB >> 2704025

Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo.

G W Rewcastle1, G J Atwell, B C Baguley, S B Calveley, W A Denny.   

Abstract

In a search for compounds related to flavoneacetic acid with activity against solid tumors, a series of methyl-, methoxy-, chloro-, nitro-, and hydroxy-substituted xanthenone-4-acetic acids have been synthesized and evaluated against subcutaneously implanted colon adenocarcinoma 38 in vivo, using a short-term histology assay as a primary screening system. A major goal of this work was to identify compounds with similar profiles of activity to that of flavoneacetic acid but of higher potency. The level of activity of the compounds appeared to depend more on the nature of the substituent than its positioning, in the order Cl greater than Me, OMe greater than NO2, OH. However, the potency of the compounds was related much more to the position rather than the nature of the substitution, with 5-substituted compounds being clearly the most dose potent. 5-Methylxanthenone-4-acetic acid has a similar level of activity to that of flavoneacetic acid in the test systems employed but is more than 7-fold as dose potent.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2704025     DOI: 10.1021/jm00124a012

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  19 in total

Review 1.  Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.

Authors:  Zhiyan Xiao; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2015-09-11       Impact factor: 12.944

2.  Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 5'6-dimethylxanthenone-4-acetic acid (Vadimezan).

Authors:  Guanjun Cheng; Jing Sun; Zvi G Fridlender; Liang-Chuan S Wang; Lai-Ming Ching; Steven M Albelda
Journal:  J Biol Chem       Date:  2010-01-29       Impact factor: 5.157

3.  Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes.

Authors:  S Zhou; R Chin; P Kestell; M D Tingle; J W Paxton
Journal:  Br J Clin Pharmacol       Date:  2001-08       Impact factor: 4.335

4.  Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice.

Authors:  M J McKeage; P Kestell; W A Denny; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

5.  Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5,6-dimethyl-xanthenone-4-acetic acid [correction of 5,6-methyl-] and flavone acetic acid.

Authors:  L M Ching; M J McKeage; W R Joseph; P Kestell; L J Zwi; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Nitric oxide: its production in host-cell-infiltrated EMT6 spheroids and its role in tumour cell killing by flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid.

Authors:  L L Thomsen; B C Baguley; W R Wilson
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid.

Authors:  M Philpott; B C Baguley; L M Ching
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  Anti-Helicobacter pylori activity of some newly synthesized derivatives of xanthone.

Authors:  Karolina Klesiewicz; Elżbieta Karczewska; Alicja Budak; Henryk Marona; Natalia Szkaradek
Journal:  J Antibiot (Tokyo)       Date:  2016-03-30       Impact factor: 2.649

9.  Induction of adrenomedullin mRNA and protein by lipopolysaccharide and paclitaxel (Taxol) in murine macrophages.

Authors:  M Zaks-Zilberman; C A Salkowski; T Elsasser; F Cuttitta; S N Vogel
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

10.  5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study.

Authors:  G J S Rustin; C Bradley; S Galbraith; M Stratford; P Loadman; S Waller; K Bellenger; L Gumbrell; L Folkes; G Halbert
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.